Proton Beam Therapy for Histologically or Clinically Diagnosed Stage I Non-Small Cell Lung Cancer (NSCLC) : The First Nationwide Retrospective Study in Japan

Autor: Shigeyuki Murayama, Kayoko Ohnishi, Takashi Ogino, Tetsuo Akimoto, Hitoshi Wada, Yoshitaka Sato, Jun-etsu Mizoe, Tomoaki Okimoto, Hideyuki Harada, Yuta Sekino, Hitoshi Ishikawa, Naoki Nakamura, Yasuhito Kikuchi, Hideyuki Sakurai, Hiromitsu Iwata, Sunao Tokumaru, Takeshi Arimura, Hiroyasu Tamamura
Jazyk: angličtina
Rok vydání: 2020
Předmět:
Adult
Male
Cancer Research
medicine.medical_specialty
Lung Neoplasms
Stage I Non-Small Cell Lung Cancer
Kaplan-Meier Estimate
Gastroenterology
Effective dose (radiation)
030218 nuclear medicine & medical imaging
03 medical and health sciences
0302 clinical medicine
Japan
Carcinoma
Non-Small-Cell Lung
Internal medicine
Proton Therapy
medicine
Carcinoma
Humans
Radiology
Nuclear Medicine and imaging
Progression-free survival
Adverse effect
Survival rate
Aged
Neoplasm Staging
Retrospective Studies
Pneumonitis
Aged
80 and over
Radiation
business.industry
Incidence
Radiotherapy Dosage
Retrospective cohort study
Middle Aged
medicine.disease
Progression-Free Survival
Radiation Pneumonitis
Survival Rate
Oncology
030220 oncology & carcinogenesis
Female
Radiodermatitis
business
Relative Biological Effectiveness
Follow-Up Studies
Zdroj: International journal of radiation oncology, biology, physics. 106(1):82-89
ISSN: 0360-3016
Popis: Purpose To investigate the efficacy and safety of proton beam therapy (PBT) for the treatment of stage I non-small cell lung cancer (NSCLC). Methods and Materials Six hundred sixty-nine patients with 682 tumors histologically or clinically diagnosed stage I NSCLC according to the seventh edition of Union for International Cancer Control who received passive-scattering PBT from April 2004 and December 2013 in Japan were retrospectively reviewed to analyze survival, local control, and toxicities. Results Of 669 patients, 486 (72.6%) were men, with a median age of 76 years (range, 42-94 years). NSCLC was histologically confirmed in 440 patients (65.7%). Clinical T stages included T1a (n = 265; 38.9%), T1b (n = 216; 31.7%), and T2a (n = 201; 29.4%). The total irradiation doses of PBT ranged from 74.4 to 131.3 biological effective dose GyE (median, 109.6 biological effective dose GyE). The median follow-up period was 38.2 months (range, 0.6-154.5 months) for all patients. The 3-year overall survival and progression-free survival rates for all patients were 79.5% and 64.1%, respectively. For patients with stage IA tumors, the 3-year overall survival and progression-free survival rates were 82.8% and 70.6%, respectively, and the corresponding rates for patients with stage IB tumors were 70.8% and 47.3%, respectively. The 3-year local progression-free rates for all, stage IA, and stage IB patients were 89.8%, 93.5%, and 79.4%, respectively. The incidence of grade 2, 3, 4, and 5 pneumonitis was 9.8%, 1.0%, 0%, and 0.7%, respectively. The incidence of grade ≥3 dermatitis was 0.4%. No grade 4 or severe adverse events, other than pneumonitis, were observed. Conclusions PBT appears to yield acceptable survival rates, with a low rate of toxicities.
Databáze: OpenAIRE
Externí odkaz: